Synta downgraded

|By:, SA News Editor

Stifel downgrades Synta Pharmaceuticals (SNTA) from Hold to Sell.

Analyst Brian Klein cites delayed data readouts, changes in clinical trial designs, management changes and the need for additional capital as reasons for the change of outlook.